Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

92
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
92
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

375
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
375
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

160
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
160
Hazard Ratio01:12

Hazard Ratio

489
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

Revue medicale de Liege·2022
Same author

[A new approach in coronary interventional cardiology: the distal radial approach].

Revue medicale de Liege·2022
Same author

[Heart failure with preserved ejection fraction (HFpEF). What's up?]

Revue medicale de Liege·2022
Same author

[The wearable cardioverter defibrillator].

Revue medicale de Liege·2022
Same author

[Tricuspid regurgitation: transcatheter treatment by TriClip®].

Revue medicale de Liege·2022
Same author

Cardiac amyloidosis: a review of the literature.

Acta cardiologica·2022
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

[The PARAGON-HF trial].

J Tridetti1, M L Nguyen Trung1, A Ancion2

  • 1Service de Cardiologie, CHU Liège, Belgique.

Revue Medicale De Liege
|February 8, 2020
PubMed
Summary
This summary is machine-generated.

The PARAGON HF trial found sacubitril/valsartan did not significantly reduce primary endpoints in heart failure with preserved ejection fraction (HFpEF). However, it reduced HF hospitalizations and improved symptoms and quality of life.

Keywords:
Angiotensin receptor neprilysin inhibitorLCZ 696Sacubitril/valsartanHeart failure with preserved ejection fraction

More Related Videos

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
09:33

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

2.6K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

859

Related Experiment Videos

Last Updated: Dec 29, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
09:33

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

2.6K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

859

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge with limited treatment options.
  • Previous trials have largely failed to demonstrate significant benefits for therapies targeting HFpEF.

Purpose of the Study:

  • To compare the efficacy of sacubitril/valsartan versus valsartan in reducing heart failure hospitalizations and cardiovascular mortality in patients with HFpEF.
  • To evaluate the safety profile of sacubitril/valsartan in this patient population.

Main Methods:

  • The PARAGON HF trial was a multicenter, randomized, double-blind study.
  • Patients with HFpEF were treated with either sacubitril/valsartan or valsartan alone.
  • Median follow-up was 35 months.

Main Results:

  • The primary endpoint (reduction in HF hospitalization and cardiovascular mortality) was not statistically significant (13% reduction, p=0.058).
  • Sacubitril/valsartan significantly reduced heart failure hospitalizations (RR 0.85) but not cardiovascular mortality.
  • Subgroup analyses suggested potential benefits in women and patients with intermediate ejection fraction.
  • Improvements in quality of life and HF symptoms were observed with sacubitril/valsartan.

Conclusions:

  • While not meeting statistical significance for the primary endpoint, sacubitril/valsartan demonstrated a trend towards benefit in HFpEF patients, particularly in reducing hospitalizations.
  • The drug improved quality of life and symptoms, with potential benefits identified in specific subgroups.
  • Increased incidence of hypotension and angioneurotic edema were noted, alongside a lower incidence of hyperkalemia.